Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
 1 a 15 de 15 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Balckwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobssen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48. [Ref.ID 100961]
2. Cita con resumen
Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gómez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens Jr FL, Gelber RD, Hortobagyi GN, Albain KS, for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32. [Ref.ID 98930]
3. Cita con resumen
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-44. [Ref.ID 93581]
4. Cita con resumen
Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lewohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9. [Ref.ID 92340]
5. Cita con resumen
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O0Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-81. [Ref.ID 90795]
6. Cita con resumen
Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367:595-604. [Ref.ID 76185]
7.Tiene citas relacionadas
Hortobagyi GN. Trastuzumab in breast cancer. Dr. Hortobagyi replies. N Engl J Med 2006;354:643. [Ref.ID 76152]
8.Tiene citas relacionadas
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6. [Ref.ID 75155]
9.Tiene citas relacionadas
Bast RC, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. N Engl J Med 2004;351:2865-7. [Ref.ID 72298]
10. Cita con resumen
Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000;355:281-3. [Ref.ID 49025]
11. Cita con resumen
Antman KH, Heitjan DF, Hortobagyi GN. High-dose chemotherapy for breast cancer. JAMA 1999;282:1701-3. [Ref.ID 47908]
12.
Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84. [Ref.ID 40436]
13.
Hortobagyi GN, Theriault RL, Seaman J. Pamidronate and metastatic breast cancer. The authors reply. N Engl J Med 1997;336:1610. [Ref.ID 32412]
14.
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma D J. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91. [Ref.ID 30606]
15.
Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994;47:223-58. [Ref.ID 21072]
Seleccionar todas
 
 1 a 15 de 15